BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Microsulis Medical Limited Sells Microwave Endometrial Ablation (MEA) to Hologic, Inc. (HOLX)


2/7/2011 7:24:59 AM

DENMEAD, England--(BUSINESS WIRE)-- Microsulis Medical Limited (http://www.microsulis.com/) announced this week that it has exclusively licensed to Hologic Inc all rights to its microwave technology in the gynecology and female urology fields of use.

From 2007 Microsulis has focused strategically on the development of its breakthrough microwave tumour ablation MTA system. “Following years of investment and technical development in 2010 we achieved CE Mark and FDA 510k clearance on our revolutionary high power Microwave Tumour Ablation (MTA) system. This breakthrough system redefines the performance benchmark for tumour ablation devices in the interventional oncology market. Through the sale of our MEA platform to Hologic, we not only open our microwave technology to the most capable device developer in the woman’s health space, but we release the value of MEA to underpin the commercialization phase of our MTA device.” commented Microsulis CEO Stuart McIntyre. “Hologic has the capability and market leadership needed to release the potential of our microwave technology to treat various female urological and gynecological conditions. There is no better company to nurture the technology in the woman’s health space.”

Hologic is the leading supplier of medical devices and products for treating women’s health conditions. The NovaSure Endometrial Ablation System is recognized worldwide as a premier product with a long track record of safety and efficacy. “We look forward to working with Hologic over the next months and years in developing value from our technology portfolio. We are pleased that our customers will continue to be supported by such a capable company.” said Stuart McIntyre.

About Microsulis Medical Limited

Founded in 1997, Microsulis Medical Ltd is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic devices. The company was initially formed following research collaboration between Chemring and the University of Bath in 1993. The company leads the field in microwave technology for endometrial ablation, tumour ablation, and venous occlusion. For more information on Microsulis Medical Limited please visit www.microsulis.com.

Contact:

Schwartz Communications, Inc. for Microsulis Charlotte Webber +44 (0)7949 872296 Microsulis@schwartz-pr.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES